NASDAQ:ABSI

Absci (ABSI) Stock Price, News & Analysis

Absci logo
$8.18 +0.60 (+7.92%)
As of 11:56 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Absci Stock (NASDAQ:ABSI)

Advanced

Key Stats

Today's Range
$7.60
▼
$8.73
50-Day Range
$7.47
▼
$12.10
52-Week Range
$2.24
▼
$12.54
Volume
2.35 million shs
Average Volume
4.33 million shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$14.90
Consensus Rating
Moderate Buy

Company Overview

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines.

The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Founded in 2011 by Sean McClain, Absci is headquartered in Vancouver, Washington. McClain serves as the company’s chief executive officer.

AI Generated. May Contain Errors.

Absci Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
62nd Percentile Overall Score

ABSI MarketRank™: 
3.10583844308 of 5 stars

Absci scored higher than 62% of companies evaluated by MarketBeat, and ranked 330th out of 859 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Absci has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on no strong buy ratings, 11 buy ratings, no hold ratings, and 1 sell rating.

  • Upside Potential

    Absci has a consensus price target of $14.90, representing about 96.6% upside from its current price of $7.58.

  • Amount of Analyst Coverage

    Absci has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Absci's stock forecast and price target.
  • Earnings Growth

    Earnings for Absci are expected to grow in the coming year, from ($0.76) to ($0.72) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Absci is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Absci is -9.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Absci has a P/B Ratio of 5.97. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    23.34% of the float of Absci has been sold short.
  • Short Interest Ratio / Days to Cover

    Absci has a short interest ratio ("days to cover") of 9.06.
  • Change versus previous month

    Short interest in Absci has recently decreased by 3.18%, indicating that investor sentiment is improving.
  • Dividend Yield

    Absci does not currently pay a dividend.

  • Dividend Growth

    Absci does not have a long track record of dividend growth.

  • News Sentiment

    Absci has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 28 news articles for Absci this week, compared to 4 articles on an average week.
  • Search Interest

    Only 13 people have searched for ABSI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • MarketBeat Follows

    9 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 29% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Absci insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    10.52% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Absci's insider trading history.
Receive ABSI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

ABSI Stock News Headlines

Absci (NASDAQ:ABSI) Stock Price Down 9.6% After Analyst Downgrade
Absci (NASDAQ:ABSI) Stock Price Target Cut by Guggenheim
Your free book is about to disappear
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
Absci Corp. (ABSI) Gets Downgraded. Here’s How Much
H.C. Wainwright Keeps Their Buy Rating on AbSci (ABSI)
Absci (NASDAQ:ABSI) Price Target Raised to $15.00
Absci's (ABSI) Buy Rating Reiterated at BTIG Research
See More Headlines

ABSI Stock Analysis - Frequently Asked Questions

Absci's stock was trading at $3.49 at the beginning of the year. Since then, ABSI shares have increased by 117.2% and is now trading at $7.58.

Absci Corporation (NASDAQ:ABSI) announced its quarterly earnings results on Thursday, November, 12th. The company reported ($0.19) EPS for the quarter, missing analysts' consensus estimates of ($0.19) by $0.00. The company had revenue of $304 thousand for the quarter, compared to the consensus estimate of $658 thousand. Absci had a negative trailing twelve-month return on equity of 61.60% and a negative net margin of 8,451.31%.
Read the conference call transcript
.

Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share.

Top institutional shareholders of Absci include State Street Corp (4.93%), Marshall Wace LLP (1.13%), Goldman Sachs Group Inc. (0.93%) and Integral Health Asset Management LLC (0.76%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Sean Mcclain, Redmile Group, Llc, Andreas Busch, Zachariah Jonasson, Todd Bedrick and Menelas N Pangalos.
View institutional ownership trends
.

Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Taiwan Semiconductor Manufacturing (TSM), Recursion Pharmaceuticals (RXRX), Palantir Technologies (PLTR), CRISPR Therapeutics (CRSP) and Marvell Technology (MRVL).

Company Calendar

Last Earnings
11/12/2026
Today
11/18/2026
Jefferies Global Healthcare Conference
11/18/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:ABSI
CIK
1672688
Fax
N/A
Employees
140
Year Founded
2011

Price Target and Rating

High Price Target
$20.00
Low Price Target
$10.00
Potential Upside/Downside
+81.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$115.18 million
Net Margins
-8,451.31%
Pretax Margin
-8,457.10%
Return on Equity
-61.60%
Return on Assets
-55.30%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
9.64
Quick Ratio
9.64

Sales & Book Value

Annual Sales
$2.80 million
Price / Sales
505.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.27 per share
Price / Book
6.45

Miscellaneous

Outstanding Shares
172,750,000
Free Float
154,573,000
Market Cap
$1.42 billion
Optionable
Optionable
Beta
2.22

Social Links

10 Stocks Powering The Next AI Boom  Cover

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

This page (NASDAQ:ABSI) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners